BLIS Technologies (NZSE:BLT) Debt-to-Equity : 0.03 (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is BLIS Technologies Debt-to-Equity?

BLIS Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NZ$0.18 Mil. BLIS Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NZ$0.21 Mil. BLIS Technologies's Total Stockholders Equity for the quarter that ended in Mar. 2024 was NZ$11.49 Mil. BLIS Technologies's debt to equity for the quarter that ended in Mar. 2024 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BLIS Technologies's Debt-to-Equity or its related term are showing as below:

NZSE:BLT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.07 Max: 0.24
Current: 0.05

During the past 13 years, the highest Debt-to-Equity Ratio of BLIS Technologies was 0.24. The lowest was 0.05. And the median was 0.07.

NZSE:BLT's Debt-to-Equity is ranked better than
72.94% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs NZSE:BLT: 0.05

BLIS Technologies Debt-to-Equity Historical Data

The historical data trend for BLIS Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BLIS Technologies Debt-to-Equity Chart

BLIS Technologies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.10

0.06

0.03

BLIS Technologies Semi-Annual Data
	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.06	0.06	0.06	0.05	0.03

Competitive Comparison of BLIS Technologies's Debt-to-Equity

For the Biotechnology subindustry, BLIS Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BLIS Technologies's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BLIS Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BLIS Technologies's Debt-to-Equity falls into.

BLIS Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BLIS Technologies's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.177	+	0.212)	/	11.488
	=	0.03

BLIS Technologies's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.177	+	0.212)	/	11.488
	=	0.03

BLIS Technologies (NZSE:BLT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

BLIS Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BLIS Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BLIS Technologies (NZSE:BLT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BLIS Technologies Ltd (NZSE:BLT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

442 Moray Place, Ground Floor, Dunedin, OTA, NZL, 9016

Website

https://www.blis.co.nz

BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets two strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 both of which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from EMEA (Europe, the Middle East, and Africa).